Hartford Funds Management Co LLC Sells 195 Shares of Eli Lilly and Company (NYSE:LLY)

Hartford Funds Management Co LLC trimmed its position in Eli Lilly and Company (NYSE:LLY) by 11.6% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,492 shares of the company’s stock after selling 195 shares during the quarter. Eli Lilly and Company accounts for 0.1% of Hartford Funds Management Co LLC’s holdings, making the stock its 23rd largest holding. Hartford Funds Management Co LLC’s holdings in Eli Lilly and Company were worth $870,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in the company. JGP Wealth Management LLC grew its holdings in shares of Eli Lilly and Company by 0.9% during the 4th quarter. JGP Wealth Management LLC now owns 1,843 shares of the company’s stock valued at $1,074,000 after purchasing an additional 16 shares during the last quarter. Patton Albertson Miller Group LLC grew its holdings in shares of Eli Lilly and Company by 2.8% during the 3rd quarter. Patton Albertson Miller Group LLC now owns 623 shares of the company’s stock valued at $335,000 after purchasing an additional 17 shares during the last quarter. Valley Wealth Managers Inc. grew its holdings in shares of Eli Lilly and Company by 1.3% during the 3rd quarter. Valley Wealth Managers Inc. now owns 1,280 shares of the company’s stock valued at $688,000 after purchasing an additional 17 shares during the last quarter. Sandy Cove Advisors LLC grew its holdings in shares of Eli Lilly and Company by 0.8% during the 4th quarter. Sandy Cove Advisors LLC now owns 2,241 shares of the company’s stock valued at $1,307,000 after purchasing an additional 17 shares during the last quarter. Finally, Lathrop Investment Management Corp grew its holdings in shares of Eli Lilly and Company by 1.2% during the 3rd quarter. Lathrop Investment Management Corp now owns 1,476 shares of the company’s stock valued at $793,000 after purchasing an additional 18 shares during the last quarter. 82.53% of the stock is owned by institutional investors.

Insider Buying and Selling at Eli Lilly and Company

In other news, major shareholder Lilly Endowment Inc sold 78,573 shares of Eli Lilly and Company stock in a transaction that occurred on Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total value of $50,920,804.11. Following the completion of the sale, the insider now directly owns 99,333,810 shares in the company, valued at $64,375,262,246.70. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.13% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the stock. Bank of America increased their price target on shares of Eli Lilly and Company from $800.00 to $1,000.00 and gave the company a “buy” rating in a research report on Friday, March 1st. Cantor Fitzgerald reissued an “overweight” rating and set a $885.00 price target (up previously from $815.00) on shares of Eli Lilly and Company in a research report on Tuesday. DZ Bank cut shares of Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price target for the company. in a research report on Wednesday, February 21st. TheStreet raised shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a research report on Friday, March 8th. Finally, BMO Capital Markets raised their target price on shares of Eli Lilly and Company from $710.00 to $865.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 7th. Three equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $731.55.

Eli Lilly and Company Stock Up 6.0 %

NYSE:LLY traded up $44.36 on Tuesday, reaching $781.56. 7,432,651 shares of the stock traded hands, compared to its average volume of 3,071,009. The company has a market capitalization of $742.61 billion, a price-to-earnings ratio of 134.75, a PEG ratio of 1.60 and a beta of 0.34. The company has a current ratio of 0.94, a quick ratio of 0.73 and a debt-to-equity ratio of 1.69. Eli Lilly and Company has a 12 month low of $392.26 and a 12 month high of $800.78. The company’s fifty day simple moving average is $761.41 and its 200 day simple moving average is $669.21.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 earnings per share for the quarter, beating analysts’ consensus estimates of $2.30 by $0.19. The business had revenue of $9.35 billion during the quarter, compared to analyst estimates of $8.95 billion. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. Eli Lilly and Company’s revenue was up 28.1% compared to the same quarter last year. During the same period last year, the business earned $2.09 EPS. Equities analysts predict that Eli Lilly and Company will post 12.51 EPS for the current fiscal year.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.